The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 05, 2025
Filed:
Feb. 13, 2024
Xencor, Inc., Pasadena, CA (US);
Janssen Biotech, Inc., Horsham, PA (US);
John R. Desjarlais, Pasadena, CA (US);
Gregory Moore, Azusa, CA (US);
Michael Hedvat, Encino, CA (US);
Juan Diaz, Anaheim Hills, CA (US);
Veronica Gusti Zeng, Duarte, CA (US);
Matthew Adam Dragovich, Rancho Cucamonga, CA (US);
Joseph Erhardt, Sellersville, PA (US);
Theresa Mcdevitt, Warminster, PA (US);
Fouad Moussa, Allentown, PA (US);
Pankaj Seth, Norristown, PA (US);
Fei Shen, Collegeville, PA (US);
Adam Zwolak, Bala Cynwyd, PA (US);
Xencor, Inc., Pasadena, CA (US);
Abstract
Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.